Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ketorolac ophthalmic - Allergan

Drug Profile

Ketorolac ophthalmic - Allergan

Alternative Names: ACULAR; ACULAR LS; ACULAR PF; ACUVAIL; Ketorolac tromethamine

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche Palo Alto LLC
  • Developer Allergan
  • Class 2 ring heterocyclic compounds; Carboxylic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrroles; Small molecules
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic conjunctivitis; Postoperative inflammation; Postoperative pain

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Postoperative-inflammation in India (Ophthalmic, Drops)
  • 24 Jul 2009 The US FDA approves ACUVAIL™, a 45% ketorolac tromethamine ophthalmic solution, for the treatment of pain and inflammation following cataract surgery
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top